OCUL

Ocular Therapeutix, Inc.

$9.01 -1.53%

Recent alerts on OCUL

All signals →

Insider trade Sale by Dugel Pravin (See Remarks)

Insider trade Sale by Nayak Sanjay (Chief Strategy Officer)

Insider trade Sale by Heier Jeffrey S. (Chief Scientific Officer)

Insider trade Sale by Kaiser Peter (Chief Development Officer)

News OCUL Sales Drop 18%

News Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)

News Ocular Therapeutix misses Q1 street views

SEC filing OCUL Reports $126M Q1 Revenue, $0.08 EPS, SOL-1 Wet AMD Phase 3 Superiority Trial Positive, AXPAXLI NDA Submission Planned, $666.7M Cash Runway to 2028

Short volume Short volume 65% of volume (3.4σ)

News EyePoint sues Ocular over claims related to lead asset

SEC filing OCUL Discloses SOL-1 Phase 3 Results for AXPAXLI in Wet AMD at Macula Society

Insider trade Sale by Pravin Dugel (Executive Chairman, President and CEO)

Insider trade Sale by Jeffrey S. Heier (Chief Scientific Officer)

Insider trade Sale by Peter Kaiser (Chief Development Officer)

Insider trade Sale by Nadia Waheed (Chief Medical Officer)

Insider trade Sale by Pravin Dugel (Executive Chairman, President and CEO)

Insider trade Sale by Donald Notman (Chief Operating Officer)

Insider trade Sale by Sanjay Nayak (Chief Strategy Officer)

Insider trade Sale by Donald Notman (Chief Operating Officer)

News Ocular drops after late-stage trial data for wet AMD therapy

News Biggest stock movers Tuesday: ZIM, CMPS, and more

SEC filing 8-K Filing

News Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid

News Ocular surges on report of Sanofi buyout bid

Get push alerts for OCUL

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS